Products Affected - Description
Terbutaline sulfate injection, 1 mg/mL, Ben Venue (formerly Bedford product)
1 mL vial, package of 10 (NDC 55390-0101-10)
Reason for the Shortage
- Ben Venue stopped production in its plant in Bedford, Ohio and closed in 2014.
- Akorn has discontinued terbutaline injection.
Terbutaline sulfate injection, 1 mg/mL, Fresenius Kabi
1 mL vial, package of 25 (NDC 63323-0665-01)
Terbutaline sulfate injection, 1 mg/mL, West-Ward
1 mL vial, package of 10 (NDC 00143-9746-10)
Estimated Resupply Dates
All presentations are currently available.
September 10, 2014; July 7, 2014; May 12, 2014; April 30, 2014; March 10, 2014; January 21, 2014; November 19, 2013; September 16, 2013; July 29, 2013; June 4, 2013; May 30, 2013; March 15, 2013; December 18, 2012; September 19, 2012; July 2, 2012; June 13, 2012; May 2, 2012; March 28, 2012; February 17, 2012; December 14, 2011; November 9, 2011; September 30, 2011; August 22, 2011; July 28, 2011; July 1, 2011, University of Utah, Drug Information Service. Copyright 2014, University of Utah, Drug Information Service.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins